3 completed. 2 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Microbiome Health Sciences: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD MHS-1031, Placebo - Gastroesophageal Reflux | Phase 2 | Completed | Microbiome Health Sciences | 255 | 2023-03-03 | 2026-07-27 |
| Tolerability Study of Panosyl-Isomaltooligosaccharides (PIMO) and a Placebo in Subjects With Heartburn Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml), Placebo 1.4 ml - Heartburn | Not applicable | Completed | Microbiome Health Sciences | 211 | 2022-02-10 | 2023-07-18 |
| Tolerability Study of Panosyl Isomaltooligosaccharides (PIMO), in Subjects With Chronic Idiopathic Constipation (CIC) MHS 1031, placebo - Constipation Chronic Idiopathic | Not applicable | Completed | Microbiome Health Sciences | 172 | 2021-09-23 | 2023-07-18 |
Gastroesophageal Reflux (2) · Heartburn (2) · Dyspepsia (1)
United States (3)
Peter Swann, MD (3)